Certolizumab pegol: new opportunities for treatment of moderate to severe plaque psoriasis

• Egile Nagusiak: A. A. Kubanov (Egilea), A. L. Bakulev (Egilea), M. I. Gluzmin (Egilea), M. M. Kokhan (Egilea), L. S. Kruglova (Egilea), N. S. Rudneva (Egilea), O. Yu. Olisova (Egilea), E. V. Sokolovsky (Egilea), M. M. Khobeish (Egilea)
• Formatua: Liburua
• Argitaratua: State Scientific Center of Dermatovenereology and Cosmetology, 2019-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Tumor necrosis factor alpha (TNF-α) is one of the key inflammatory cytokines in the pathogenesis of psoriasis and psoriatic arthritis, and its inhibition with genetically engineered biological drugs ensures control of the main symptoms of these diseases. Certolizumab pegol is a PEGylated (linked to...